ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025
Transient Increased Risk of Shingles Post-Shingrix Vaccination: Self-Controlled Case-Series Analysis.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFollowing the introduction of a funded recombinant shingles vaccine (RZV; Shingrix, GlaxoSmithKline) vaccination program in adults aged ≥65 years in Australia, clinician reports of shingles presentations shortly after vaccination emerged. We investigated whether there was an increase in shingles risk immediately post-RZV vaccination in southeastern Australia.
methodsTwo independent datasets-a general practice dataset and a statewide linked dataset-were analyzed separately using self-controlled case series (SCCS) analyses with 21 days postvaccination as the risk window. The observation period was 1 January 2023 to 30 April 2025. Adults ≥18 years were included, with analyses stratified by age (<65 and ≥65 years) and sex. We calculated the rate of incident shingles in time periods relative to vaccination, along with attributable risk and the risk of postherpetic neuralgia (PHN).
resultsThe primary care SCCS analysis found an 11-fold increase (relative incidence, 10.96; 95% CI, 10.34-11.62; P < .0001) in shingles presentations within 21 days post-dose 1 of RZV vaccination in adults ≥65 in the general practice dataset only. No increase was detected in younger adults. Following dose 2, the risk of shingles presentations was reduced in all age groups. Vaccine recipients had a 73% reduction in shingles following 2 doses. PHN risk was not increased.
conclusionsThere is a transient increase in shingles presentations shortly after dose 1 of RZV vaccination in adults ≥65 years; however, these cases are likely to be mild and there is clear evidence of vaccine effectiveness after the completion of 2 doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.